In Melbourne, Australia and Indianapolis on September 10, 2025, Telix Pharmaceuticals Limited disclosed that the first patient has been administered in a Phase 3 clinical trial. The trial is focused on broadening the uses of Illuccix® and Gozellix® kits, which are utilized for the production of gallium-68 (68 Ga) gozetotide injection. The objective is to encompass prostate cancer diagnosis within the possible indications for these products. Telix Pharmaceuticals Limited is listed on the ASX as TLX and on the NASDAQ as TLX.